Diagnostic Value of a Group of MicroRNA Genes Hypermethylated in Ovarian Carcinoma


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

The study was designed to determine genes of microRNAs hypermethylated in malignant ovarian tumors and to select new diagnostic and prognostic markers of the disease and effective system of markers. Using methyl-specific PCR and a representative sample of 54 ovarian cancer specimens, we determined 5 microRNA genes (MIR-34b/c, MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) hypermethylated in the majority of tumor samples in comparison with paired samples of histologically unchanged tissue (48-57% vs. 4-19%, p<0.001). Using ROC-analysis, we selected an effective system of 4 markers for diagnosis of ovarian cancer (MIR-9-1, MIR-124-3, MIR-129-2, and MIR-107) characterized by high sensitivity and specificity (up to 87-94% at AUC=0.92) relative to the conventional norm (54 paired samples of histologically unchanged tissue) and absolute norm (18 ovarian tissue samples from subjects who died from non-tumor diseases). It was also shown that methylation of MIR-129-2, MIR-9-1, and MIR-34b/c genes is significantly (p<0.01) correlated with the clinical stage or the presence of metastases. The results indicate that epigenetic modifications of the studied microRNA genes are involved in the pathogenesis and progression of ovarian cancer and attest to their diagnostic and prognostic potential.

Об авторах

E. Braga

Research Institute of General Pathology and Pathophysiology; Research Center of medical Genetics

Автор, ответственный за переписку.
Email: eleonora10_45@mail.ru
Россия, Moscow; Moscow

V. Loginov

Research Institute of General Pathology and Pathophysiology; Research Center of medical Genetics

Email: eleonora10_45@mail.ru
Россия, Moscow; Moscow

E. Filippova

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow

A. Burdennyi

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow

I. Pronina

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow

T. Kazubskaya

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

D. Khodyrev

Federal Scientific and Clinical Center of Specialized Medical Assistance and Medical Technologies, Federal Medical and Biological Agency of the Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

D. Utkin

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

D. Kushlinskii

V. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

L. Adamyan

V. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

N. Kuslinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

© Springer Science+Business Media, LLC, part of Springer Nature, 2018

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).